



Norman J. Lacayo, MD

Associate Professor of Pediatrics (Hematology and Oncology) at the Lucile Salter Packard Children's Hospital

Pediatrics - Hematology & Oncology

CLINICAL OFFICES

- **Bass Cancer Center for Childhood Cancer and Blood Diseases**

725 Welch Rd

MC 5913

Palo Alto, CA 94304

Tel (650) 497-8953

Fax (650) 497-8959

Bio

CLINICAL FOCUS

- Hematology/Oncology/Stem Cell Transplant, Pediatric
- Oncology (Cancer), Pediatric
- AML, childhood and adolescent/young adult
- ALL, childhood and adolescent/young adult
- lymphoblastic lymphoma, childhood
- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Associate Professor - Med Center Line, Pediatrics - Hematology & Oncology
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Member, Cancer Center, (2007- present)
- Myeloid Steering Committee, Children's Oncology Group, (2007- present)

HONORS AND AWARDS

- Member, Alpha Omega Alpha (1990)
- New Approaches in Pediatric Myeloid Leukemia, V Foundation (10/09-09/12)
- Banking Acute Leukemia Specimens at Lucile Packard Children's Hospital: Hyundai Infrastructure Grant, Hyundai Foundation (10/11-09/12)
- Molecular and Pharmacologic Correlates of Acute Myeloid Leukemia in Down Syndrome, NIH ROI subcontract from Wayne State University (01/09-04/16)

PROFESSIONAL EDUCATION

- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (1996)
- Medical Education: University of California at San Francisco School of Medicine (1989) CA
- Internship: UCSF Medical Center (1990) CA
- Residency: UCSF Medical Center (1992) CA
- Fellowship: Stanford University Medical Center (1995) CA
- MD, U.C., San Francisco, Medicine (1989)
- BA, U. C., Berkeley, Biochemistry (1985)

LINKS

- Research Gate: http://www.researchgate.net/profile/Norman_Lacayo/

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Pediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.

CLINICAL TRIALS

- A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma, Recruiting
- A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children, Recruiting
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia, Recruiting
- Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children, Recruiting
- Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies, Recruiting
- Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment, Recruiting
- Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage, Recruiting
- A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL), Not Recruiting
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors, Not Recruiting
- Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects, Not Recruiting
- Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment, Not Recruiting
- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia, Not Recruiting
- Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients., Not Recruiting
- Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome, Not Recruiting
- Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome, Not Recruiting
- Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss, Not Recruiting
- Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I, Not Recruiting
- Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia, Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Yuntao Xia

Publications

PUBLICATIONS

- **Combination BCL-2 Inhibitor Therapy with Venetoclax and Navitoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma**
Jabbour, E., Mullighan, C. G., Pullarkat, V. A., Lacayo, N. J., Bajel, A., Rubnitz, J., Leonard, J., Khaw, S., Vear, S. I., Alexander, T., Norris, R., Salem, A., Schmidt, et al
CIG MEDIA GROUP, LP.2019: S184–S185
- **Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Rubnitz, J. E., Lacayo, N. J., Inaba, H., Heym, K., Ribeiro, R. C., Taub, J., McNeer, J., Degar, B., Schiff, D., Yeoh, A. E., Coustan-Smith, E., Wang, L., Triplett, et al
2019: JCO1900327
- **A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.** *Journal for immunotherapy of cancer*
Nguyen, R., Wu, H., Pounds, S., Inaba, H., Ribeiro, R. C., Cullins, D., Rooney, B., Bell, T., Lacayo, N. J., Heym, K., Degar, B., Schiff, D., Janssen, et al
2019; 7 (1): 81
- **Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells**
Chae, H., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Huang, M., Sumarsono, et al
AMER SOC HEMATOLOGY.2018
- **Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma**
Alexander, T., Lacayo, N. J., Pullarkat, V. A., Jabbour, E. J., Khaw, S., Mullighan, C. G., Bajel, A., Leonard, J., Norris, R., Rubnitz, J., Vear, S. I., Schmidt, M., Tong, et al
AMER SOC HEMATOLOGY.2018
- **Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof of Concept Study in Patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Theruvath, A. J., Nejadnik, H., Muehe, A. M., Gassert, F., Lacayo, N. J., Goodman, S. B., Daldrup-Link, H. E.
2018
- **Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma**
Hantel, A., Wynne, J., Lacayo, N., Khaw, S., Rubnitz, J., Mullighan, C., Schmidt, M., Zhou, Y., Ross, J. A., Rosenwinkel, L., Kim, S., Jabbour, E., Alexander, et al
CIG MEDIA GROUP, LP.2018: S184–S185
- **Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.** *Nature medicine*
Good, Z., Sarno, J., Jager, A., Samusik, N., Aghaepour, N., Simonds, E. F., White, L., Lacayo, N. J., Fantl, W. J., Fazio, G., Gaipa, G., Biondi, A., Tibshirani, et al
2018; 24 (4): 474–83
- **The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations**
Kumar, J., Nagy, A., Lacayo, N., Gotlib, J., Zehnder, J. L., Ohgami, R.
NATURE PUBLISHING GROUP.2018: 529
- **Nicosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways** *ONCOTARGET*
Chae, H., Cox, N., Dahl, G. V., Lacayo, N. J., Davis, K. L., Capolicchio, S., Smith, M., Sakamoto, K. M.

2018; 9 (4): 4301–17

- **Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.** *Blood*
Taub, J. W., Berman, J. N., Hitzler, J. K., Sorrell, A. D., Lacayo, N. J., Mast, K., Head, D., Raimondi, S., Hirsch, B., Ge, Y., Gerbing, R. B., Wang, Y., Alonzo, et al
2017
- **The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia**
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 358A–359A
- **The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings**
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
- **A Detailed Multi parameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study**
Segal, J., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
- **Detailed Multiparameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study**
Segal, J., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
- **The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings**
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
- **The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia**
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 358A–359A
- **Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Alexander, T. B., Lacayo, N. J., Choi, J. K., Ribeiro, R. C., Pui, C., Rubnitz, J. E.
2016; 34 (34): 4094-?
- **Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.** *Leukemia*
Mitton, B., Chae, H., Hsu, K., Dutta, R., Aldana-Masangkay, G., FERRARI, R., Davis, K., Tiu, B. C., Kaul, A., Lacayo, N., Dahl, G., Xie, F., Li, et al
2016
- **Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA** *LEUKEMIA*
Chae, H., Mitton, B., Lacayo, N. J., Sakamoto, K. M.
2015; 29 (6): 1379-1389
- **Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial**
Taub, J. W., Berman, J. N., Hitzler, J. K., Sorrell, A. D., Lacayo, N. J., Mast, K., Head, D. R., Raimondi, S. C., Hirsch, B. A., Gerbing, R. B., Alonzo, T. A., Campana, D., Coustan-Smith, et al
AMER SOC HEMATOLOGY.2014
- **Altered resting state functional connectivity in young survivors of acute lymphoblastic leukemia.** *Pediatric blood & cancer*
Kesler, S. R., Gugel, M., Pritchard-Berman, M., Lee, C., Kutner, E., Hosseini, S. M., Dahl, G., Lacayo, N.
2014; 61 (7): 1295-1299
- **Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group** *BRITISH JOURNAL OF HAEMATOLOGY*

- Lacayo, N. J., Alonzo, T. A., Gayko, U., Rosen, D. B., Westfall, M., Purvis, N., Putta, S., Louie, B., Hackett, J., Cohen, A. C., Cesano, A., Gerbing, R., Ravindranath, et al
2013; 162 (2): 250-262
- **Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421** *LEUKEMIA*
O'Brien, M. M., Cao, X., Pounds, S., Dahl, G. V., Raimondi, S. C., Lacayo, N. J., Taub, J., Chang, M., Weinstein, H. J., Ravindranath, Y., Inaba, H., Campana, D., Pui, et al
2013; 27 (3): 731-734
 - **COMPARISON OF HIGH-THROUGHPUT SEQUENCING AND FLOW CYTOMETRY FOR MEASURING MINIMAL RESIDUAL DISEASE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A CHILDREN'S ONCOLOGY GROUP COHORT**
Gawad, C., Borowitz, M., Dahl, G., Devidas, M., Faham, M., Moorhead, M., Wood, B., Zheng, J., Loh, M., Lacayo, N.
SPRINGER.2013: S23-S24
 - **AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin** *PLOS ONE*
Rosen, D. B., Harrington, K. H., Cordeiro, J. A., Leung, L. Y., Putta, S., Lacayo, N., Laszlo, G. S., Gudgeon, C. J., Hogge, D. E., Hawtin, R. E., Cesano, A., Walter, R. B.
2013; 8 (1)
 - **Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia** *BLOOD*
Gawad, C., Pepin, F., Carlton, V. E., Klinger, M., Logan, A. C., Miklos, D. B., Faham, M., Dahl, G., Lacayo, N.
2012; 120 (22): 4407-4417
 - **Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Gawad, C., Borowitz, M. J., Dahl, G. V., Devidas, M., Faham, M., Moorhead, M., Wood, B. L., Zheng, J., Loh, M. L., Lacayo, N. J.
AMER SOC HEMATOLOGY.2012
 - **Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML** *LEUKEMIA RESEARCH*
Rosen, D. B., Cordeiro, J. A., Cohen, A., Lacayo, N., Hogge, D., Hawtin, R. E., Cesano, A.
2012; 36 (7): 900-904
 - **Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types** *PLOS ONE*
Salzman, J., Gawad, C., Wang, P. L., Lacayo, N., Brown, P. O.
2012; 7 (2)
 - **Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region in Diagnostic Samples of Pediatric Acute Lymphoblastic Leukemia Identifies Hundreds of Clonal Subpopulations with Multiple Immunophenotypes** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Gawad, C., Faham, M., Willis, T., Moorhead, M., Carlton, V., Zheng, J., Klinger, M., Dahl, G. V., Lacayo, N. J.
AMER SOC HEMATOLOGY.2011: 624-24
 - **Dorsolateral Midbrain MRI Abnormalities and Ocular Motor Deficits Following Cytarabine-Based Chemotherapy for Acute Myelogenous Leukemia** *JOURNAL OF NEURO-OPHTHALMOLOGY*
Doan, T., Lacayo, N., Fisher, P. G., Liao, Y. J.
2011; 31 (1): 52-53
 - **A pilot study of an online cognitive rehabilitation program for executive function skills in children with cancer-related brain injury** *BRAIN INJURY*
Kesler, S. R., Lacayo, N. J., Jo, B.
2011; 25 (1): 101-112
 - **Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial** *LANCET ONCOLOGY*
Rubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N. J., Cao, X., Meshinchi, S., Degar, B., Airewele, et al
2010; 11 (6): 543-552
 - **Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group** *PEDIATRIC BLOOD & CANCER*
O'Brien, M. M., Lacayo, N. J., Lum, B. L., Kshirsagar, S., Buck, S., Ravindranath, Y., Bernstein, M., Weinstein, H., Chang, M. N., Arceci, R. J., Sikic, B. I., Dahl, G. V.

2010; 54 (5): 694-702

- **Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML** *BLOOD*
Pollard, J. A., Alonzo, T. A., Gerbing, R. B., Ho, P. A., Zeng, R., Ravindranath, Y., Dahl, G., Lacayo, N. J., Becton, D., Chang, M., Weinstein, H. J., Hirsch, B., Raimondi, et al
2010; 115 (12): 2372-2379
- **WT1 Expression at Diagnosis Does Not Predict Survival in Pediatric AML: A Report From the Children's Oncology Group** *PEDIATRIC BLOOD & CANCER*
Noronha, S. A., Farrar, J. E., Alonzo, T. A., Gerbing, R. B., Lacayo, N. J., Dahl, G. V., Ravindranath, Y., Arceci, R. J., Loeb, D. M.
2009; 53 (6): 1136-1139
- **Speeding the Flow Toward Personalized Therapy in Childhood Acute Leukemia** *PEDIATRIC BLOOD & CANCER*
Simonds, E. F., Davis, K. L., Lacayo, N. J.
2009; 53 (4): 525-526
- **Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia** *CANCER GENETICS AND CYTOGENETICS*
Schiffman, J. D., Wang, Y., McPherson, L. A., Welch, K., Zhang, N., Davis, R., Lacayo, N. J., Dahl, G. V., Faham, M., Ford, J. M., Ji, H. P.
2009; 193 (1): 9-18
- **Genomics of childhood leukemias: The virtue of complexity** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B. I., Tibshirani, R., Lacayo, N. J.
2008; 26 (27): 4367-4368
- **Tissue microarrays from bone marrow aspirates for high-throughput assessment of immunohistologic markers in pediatric acute leukemia** *PEDIATRIC AND DEVELOPMENTAL PATHOLOGY*
Hazard, F. K., Zhao, S., Schiffman, J. D., Lacayo, N. J., Dahl, G. V., Natkunam, Y.
2008; 11 (4): 283-290
- **Acute leukemia in children** *DM DISEASE-A-MONTH*
O'Brien, M. M., Lacayo, N. J.
2008; 54 (4): 202-225
- **The incidence and clinical significance of nucleophosmin mutations in childhood AML** *BLOOD*
Brown, P., McIntyre, E., Rau, R., Meshinchi, S., Lacayo, N., Dahl, G., Alonzo, T. A., Chang, M., Arceci, R. J., Small, D.
2007; 110 (3): 979-985
- **Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias** *JOURNAL OF CLINICAL ONCOLOGY*
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., Rowe, J. M., Goldstone, A. H., O'Dwyer, P. J., Paietta, E., Sikic, B. I.
2007; 25 (11): 1341-1349
- **Gene expression profiling predicts outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421.** *48th Annual Meeting of the American-Society-of-Hematology*
Lacayo, N. J., O'Brien, M., Jain, S., Meshinchi, S., Yu, R., Juric, D., Chang, M. N., Tebshirani, R., Ravindranath, Y., Weinstein, H. J., Sikic, B. I., Van Houten Dahl, G.
AMER SOC HEMATOLOGY.2006: 542A-542A
- **Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias.** *48th Annual Meeting of the American-Society-of-Hematology*
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., Rowe, J. M., Goldstone, A. H., O'Dwyer, P. J., Paietta, E., Sikic, B. I.
AMER SOC HEMATOLOGY.2006: 520A-520A
- **CpG island methylator phenotype and childhood leukemia** *CLINICAL CANCER RESEARCH*
Lacayo, N. J., Di Martino, J. F., Wei, M. C., Dahl, G. V.
2006; 12 (16): 4787-4789
- **Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein** *LEUKEMIA*
DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., Ravindranath, Y., Yu, R., Sikic, B., Raimondi, S. C., Dahl, G.

2006; 20 (3): 426-432

- **Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421** *BLOOD*
Becton, D., Dahl, G. V., Ravindranath, Y., Chang, M. N., Behm, F. G., Raimondi, S. C., Head, D. R., Stine, K. C., Lacayo, N. J., Sikic, B. I., Arceci, R. J., Weinstein, H.
2006; 107 (4): 1315-1324
- **Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421.** *47th Annual Meeting of the American-Society-of-Hematology*
Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., Yu, R., Juric, D., Chang, M., Willman, C., Tibshirani, R., Ravindranath, Y., Sikic, B., Weinstein, et al
AMER SOC HEMATOLOGY.2005: 667A-667A
- **Osteonectin/SPARC is epigenetically silenced in AML with MLL gene rearrangements and selectively inhibits the growth of MLL rearranged cell lines** *46th Annual Meeting of the American-Society-of-Hematology*
DiMartino, J. F., Lacayo, N. J., Varadi, M., Ravindranath, Y., Yu, R., Sikic, B., Raimondi, S. C., Dahl, G. V.
AMER SOC HEMATOLOGY.2004: 314A-314A
- **Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes** *BLOOD*
Lacayo, N. J., Meshinchi, S., Kinnunen, P., Yu, R., Wang, Y., Stuber, C. M., Douglas, L., Wahab, R., Becton, D. L., Weinstein, H., Chang, M. N., Willman, C. L., Radich, et al
2004; 104 (9): 2646-2654
- **Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valsopodar) in multidrug-resistant cells.** *Journal of experimental therapeutics & oncology*
Lacayo, N. J., Duran, G. E., Sikic, B. I.
2003; 3 (3): 127-135
- **Preferential expression of a mutant allele of the amplified MDR1 (ABC1) gene in drug-resistant variants of a human sarcoma** *GENES CHROMOSOMES & CANCER*
Chen, G. K., Lacayo, N. J., Duran, G. E., Wang, Y., Bangs, C. D., Rea, S., Kovacs, M., Cherry, A. M., Brown, J. M., Sikic, B. I.
2002; 34 (4): 372-383
- **Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia** *LEUKEMIA*
Lacayo, N. J., Lum, B. L., Becton, D. L., Weinstein, H., Ravindranath, Y., Chang, M. N., Bomgaars, L., Lauer, S. J., Sikic, B. I., Dahl, G. V.
2002; 16 (5): 920-927
- **Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Dahl, G. V., Lacayo, N. J., Brophy, N., Dunussi-Joannopoulos, K., Weinstein, H. J., Chang, M. R., Sikic, B. I., Arceci, R. J.
2000; 18 (9): 1867-1875
- **Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335)** *MOLECULAR PHARMACOLOGY*
Chen, G. K., Lacayo, N. J., Duran, G. E., Cohen, D., Sikic, B. I.
2000; 57 (4): 769-777
- **Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Chen, G., Duran, G. E., Steger, K. A., Lacayo, N. J., Jaffrezou, J. P., Dumontet, C., Sikic, B. I.
1997; 272 (9): 5974-5982